HIV increases the risk of heart failure through several overlapping pathways: chronic inflammation that scars heart tissue, viral proteins that directly damage heart muscle cells, gut barrier breakdown that fuels bodywide immune activation, and metabolic changes driven by both the virus and its treatment. People living with HIV have a heart failure prevalence of about 7.2%, compared to 4.4% in the general population, a relative risk roughly 66% higher. That elevated risk is most pronounced in younger people and women.
Chronic Inflammation and Heart Scarring
The most significant driver of HIV-related heart failure is persistent, low-grade inflammation. Even when antiretroviral therapy suppresses the virus to undetectable levels, the immune system doesn’t fully stand down. Inflammatory signaling molecules and coagulation markers remain elevated in people living with HIV, and multiple studies have confirmed these biomarkers predict cardiovascular events and death in this population.
Over years, this ongoing inflammation triggers a process called myocardial fibrosis, where collagen accumulates in heart tissue. Think of it as scar tissue slowly replacing flexible, functioning muscle. The heart becomes stiffer and less able to fill with blood properly, leading to a form of heart failure where the heart pumps normally but can’t relax enough between beats. This same fibrosis pattern appears in lymphoid tissue and the liver of people with HIV, suggesting it’s a systemic consequence of immune activation rather than something unique to the heart. The fibrosis contributes to diastolic dysfunction (difficulty filling), heart failure, and in some cases sudden cardiac death.
Direct Damage From Viral Proteins
HIV doesn’t need to infect heart cells to harm them. The virus produces surface proteins, most notably one called gp120, that can trigger heart muscle cells to self-destruct through a programmed cell death process. In laboratory studies, gp120 from multiple HIV strains caused equal levels of damage to heart cells by disrupting their mitochondria, the structures that generate energy for muscle contraction. The heart cells’ internal power supply essentially short-circuits, releasing signals that push the cell toward death.
Interestingly, while HIV can enter heart muscle cells, it doesn’t replicate inside them. The damage comes not from active infection but from the toxic effects of viral proteins circulating in the bloodstream. Over time, this gradual loss of heart muscle cells weakens the heart’s ability to pump effectively, contributing to a form of heart failure characterized by reduced pumping strength.
Gut Leakage and Immune Activation
HIV attacks immune cells concentrated in the gut lining early in infection, damaging the intestinal barrier. When that barrier breaks down, fragments of gut bacteria leak into the bloodstream. One of the most harmful is a bacterial component called LPS, which acts like an alarm signal. Once in the blood, LPS binds to immune receptors and triggers a wave of inflammatory responses, including the release of pro-inflammatory molecules from immune cells throughout the body.
This matters for the heart in several specific ways. The same immune receptor that LPS activates has been found in atherosclerotic plaque, the fatty deposits that narrow arteries. Blood levels of LPS and related markers have been linked to future cardiovascular disease risk. Another marker of this pathway, a molecule shed by activated immune cells called sCD14, has been associated with high blood pressure, worsening artery disease, and increased mortality in people living with HIV. A gut-derived compound called TMAO also appears to accelerate artery damage in this population, partially through immune activation. These connections hold even after accounting for traditional risk factors like cholesterol and blood pressure, pointing to a distinct, HIV-specific cardiovascular threat.
Metabolic Side Effects of Treatment
Some antiretroviral medications, particularly older ones, carry their own cardiac risks. A class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs), long a foundation of HIV treatment, can damage mitochondria in heart tissue. The drug zidovudine (AZT) has been shown to reduce the replication of mitochondrial DNA, impairing energy production in muscle cells in a dose-dependent way. Stavudine (d4T) produces similar effects. Both drugs have been linked to cardiomyopathy, a weakening of the heart muscle. Another NRTI, didanosine, also appears toxic to mitochondria. By contrast, lamivudine (3TC) showed no cardiac impact in the same studies, illustrating that this toxicity is drug-specific, not universal to the class.
Beyond direct mitochondrial damage, some antiretroviral drugs, especially older protease inhibitors, contribute to a syndrome of fat redistribution called lipodystrophy. People with this condition lose fat under the skin while accumulating it around the organs in the abdomen. This pattern drives insulin resistance, elevated blood fats, and impaired blood clotting, all of which raise cardiovascular risk. The combination of abnormal fat distribution and metabolic dysfunction creates conditions that stress the heart over time. Newer antiretroviral regimens carry substantially lower metabolic risk, but many people worldwide, particularly in lower-income countries, still receive older drugs.
Two Types of Heart Failure in HIV
Heart failure isn’t a single condition. It comes in two main forms: one where the heart becomes too weak to pump enough blood out (reduced ejection fraction), and one where the heart pumps adequately but is too stiff to fill properly between beats (preserved ejection fraction). HIV is associated with both. In a large study of U.S. veterans, among heart failure cases in HIV-positive participants, about 37% had the reduced-pumping type and roughly 35% had the preserved-filling type, with an additional 15% falling in a borderline category.
This split reflects the different mechanisms at work. Chronic inflammation and fibrosis tend to stiffen the heart, producing the preserved-ejection-fraction type. Direct cell death from viral proteins and mitochondrial toxicity from medications weaken the muscle itself, producing the reduced-ejection-fraction type. In practice, many people experience a combination of these processes, and the type of heart failure that develops depends on which mechanisms predominate over time.
Screening and Early Detection
Because heart failure in HIV can develop without obvious early symptoms, screening plays an important role. Current guidelines recommend calculating a 10-year cardiovascular risk score at least annually for people with HIV aged 40 to 75, and performing lipid screening at entry into care, after viral suppression is achieved, and then on a regular schedule based on age and risk factors. For women with HIV, guidelines emphasize aggressive risk factor management and prompt evaluation of any cardiac symptoms, given their disproportionately elevated relative risk.
A blood test measuring a protein called NT-proBNP can help flag heart stress before full-blown heart failure develops. Elevated levels, defined as above 164 ng/liter in people under 60 and above 225 ng/liter in those 60 and older, have been associated with cardiovascular problems in people with HIV. This biomarker is not specific to HIV-related heart disease, but it provides a useful early warning that the heart is under strain, prompting further evaluation with imaging or other testing.